Enovis Corporation (ENOV)

Market Cap	2.24B
Revenue (ttm)	2.11B
Net Income (ttm)	-825.49M
Shares Out	56.96M
EPS (ttm)	-14.93
PE Ratio	n/a
Forward PE	12.44
Dividend	n/a
Ex-Dividend Date	n/a

Volume	590,102
Open	40.30
Previous Close	40.00
Day's Range	39.09 - 40.70
52-Week Range	35.14 - 62.79
Beta	2.15
Analysts	Buy
Price Target	58.50 (+48.44%)
Earnings Date	May 1, 2025

About ENOV

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The company’s Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management,...

• Industry: Specialty Industrial Machinery
• Sector: Industrials
• IPO Date: May 8, 2008
• Employees: 7,367
• Stock Exchange: NYSE
• Ticker Symbol: ENOV
• Website: https://www.enovis.com

Financial Performance

In 2024, Enovis's revenue was $2.11 billion, an increase of 23.46% compared to the previous year's $1.71 billion. Losses were -$825.49 million, 2381.9% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for ENOV stock is "Buy." The 12-month stock price forecast is $58.5, which is an increase of 48.44% from the latest price.

Price Target

$58.5

(48.44% upside)

Analyst Consensus: Buy